Trial Profile
Neoadjuvant treatment of glioblastomas with marked or severe inaugural neurological deficit with bevacizumab and temozolomide before any radiotherapy. Multicenter phase II study.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 May 2013
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms TEMOBEVA
- 06 May 2013 New trial record